India Pre-Market Regulatory Roundup — October 19, 2026

18-10-2026

YES Bank Limited informed BSE that Axis Trustee Services Limited, acting as Debenture Trustee, requested the status of the annual coupon due on 18 October 2026 on its 9.00% Perpetual Subordinated Unsecured Basel III Compliant Additional Tier I Bonds (Series II, ISIN INE528G08394). The Bank stated that coupon payment is subject to the Supreme Court of India's judgement dated 15 October 2026 and the conditionalities in the Information Memorandum, and that it is evaluating the implications of the judgement, including all available legal options. No coupon payment status was confirmed in the filing.

• · Coupon due date: 18 October 2026; payment status is contingent on the Supreme Court judgement dated 15 October 2026 and Information Memorandum conditionalities
• · Axis Trustee also referenced ISIN INE528G08352, indicating a second bond series under the same trusteeship
• · Axis Trustee's request was made under Regulation 15 of the SEBI (Debenture Trustees) Regulations, 1993 and SEBI circular dated 28 September 2026
• · Bank references prior disclosures dated 15-17 October 2026 on the judgement and its results announcement of 17 October 2026

18-10-2026

Saisrushti (Kengeri) Projects Private Limited filed a Statement of Deviation or Variation confirming it raised INR 50 Crore through a private placement of Non-Convertible Debentures on May 20, 2022. The full amount was used for refinancing and extinguishing the existing loan and other senior debt obligations, with no deviation or variation in the use of funds and no modified objects or approvals required. The filing is routine compliance with no negative or flat performance metrics disclosed.

• · Deviation or variation in use of funds: NO
• · Audit committee and auditors reported no comments
• · Report covers the period ended not applicable (one-time fund-raise disclosure)

18-10-2026

Akara Capital Advisors Private Limited has confirmed under Regulation 57(1) of SEBI (LODR) Regulations, 2015 that it made timely monthly interest payment to all bondholders of record as of 3rd October, 2026. The payment of Rs. 44,56,978.27 (after TDS) on ISIN INE08XP07530, against an issue size of Rs. 47,50,00,000, was made on 16th October, 2026, ahead of the 18th October, 2026 due date. No redemption or maturity payments were made in the period.

• · Interest payment record date was 3rd October, 2026; actual payment date was 16th October, 2026, two days ahead of the 18th October, 2026 due date
• · Interest payment frequency is monthly with no change in frequency
• · No delay or reason for non-payment was reported
• · No redemption, put/call, or maturity payments were made on the instrument

18-10-2026

Akara Capital Advisors Private Limited has fixed Tuesday, 3 November 2026 as the record date for determining which debenture holders are eligible to receive interest on its Non-Convertible Debentures (NCDs) allotted on 18 September 2026. The intimation was filed with the Bombay Stock Exchange under Regulation 60(2) of the SEBI (LODR) Regulations, 2015. The filing contains no monetary amounts, coupon rates, or other quantitative financial metrics.

• · Record date for debenture interest eligibility: Tuesday, 3 November 2026
• · NCDs were allotted on 18 September 2026
• · BSE Scrip Code: 978176; ISIN: INE08XP07530
• · Filing made under Regulation 60(2) of SEBI (LODR) Regulations, 2015 as prior intimation of record date

18-10-2026

Akara Capital Advisors Private Limited confirmed timely monthly interest payment to all bondholders of record and made a partial redemption on its debt securities (ISIN INE08XP07449) under Regulation 57(1) of SEBI LODR. Interest of Rs. 17,57,655.08 (after TDS) was paid on 16 October 2026 against a due date of 17 October 2026, and a partial redemption of Rs. 4,69,23,030 was made on the same date, leaving an outstanding amount of Rs. 14,07,69,700 against an original issue size of Rs. 61,00,00,000.

• · Interest payment record date was 2 October 2026; due date 17 October 2026; actual payment 16 October 2026
• · Previous interest and redemption payments were both made on 16 September 2026
• · Redemption was partial on a face value basis, with reason stated as partial redemption; no call, put, or conversion options were exercised
• · Interest frequency is monthly with no change in payment schedule
• · No reason for non-payment or delay was reported

18-10-2026

Akara Capital Advisors Private Limited confirmed under Regulation 57(1) of the SEBI LODR Regulations that it made timely monthly interest payment on its debt securities (ISIN INE08XP07415). Interest of Rs. 26,75,536.01 (after TDS) was paid on 16th October, 2026, ahead of the 17th October, 2026 due date, against an issue size of Rs. 30,00,00,000. No redemption or maturity payments were made during the period.

• · Interest payment record date was 2nd October, 2026; due date 17th October, 2026; actual payment made 16th October, 2026
• · Previous interest payment was made on 16th September, 2026, confirming a monthly payment cadence with no change in frequency
• · No redemption, put/call, or maturity payments were made; no reason for delay or non-payment was reported

19-10-2026

Rossari Biotech reported record Q2 FY27 consolidated revenue of Rs. 697.6 crore (+19.0% YoY) and H1 FY27 revenue of Rs. 1,394.8 crore (+23.5% YoY), with EBITDA of Rs. 87.0 crore (+21.0% YoY) and PAT of Rs. 38.9 crore (+5.4% YoY, subdued by higher depreciation). The Board approved leasing land to its wholly owned subsidiary Rossari International Limited Company for a greenfield facility in Saudi Arabia. Mixed performance: the Institutional and B2C businesses were flat on revenue (+2% Q2 YoY), Agro was sluggish, and PAT margin contracted to 5.6% from 6.3%.

• · Working capital cycle improved to 86 days (Sep 2026) from 97 days (Mar 2026)
• · Cash flow from operations of Rs. 131 crore in H1 FY27
• · HPPC revenue grew 18% YoY in Q2 FY27, TSC grew 26%, AHN grew 11%
• · Export share of revenue was 31% in Q2 FY27 vs 28% in Q2 FY26
• · Agro business was sluggish due to El Niño
• · Excluding Institutional and B2C, Q2 FY27 EBITDA margin was 14.1%, while Institutional and B2C EBITDA margin declined to -2.5%
• · PAT remained subdued due to higher depreciation from long-term project investments (D&A rose to Rs. 30.1 crore in Q2 FY27 from Rs. 18.2 crore)
• · Finance costs rose to Rs. 8.7 crore in Q2 FY27 from Rs. 6.1 crore

19-10-2026

Rossari Biotech reported its highest-ever quarterly revenue of Rs. 697.6 crore (up 19.0% YoY) and EBITDA of Rs. 87.0 crore (up 20.9% YoY) for Q2 FY27, with H1 FY27 revenue of Rs. 1,394.8 crore (up 23.4% YoY). However, Profit After Tax was subdued at Rs. 38.9 crore in Q2 due to higher depreciation from long-term investments, EBITDA margin for H1 declined 40 bps to 12.0%, and the Agro business was sluggish due to El Niño. The Board also approved leasing land to a wholly owned subsidiary for a greenfield manufacturing facility in the Kingdom of Saudi Arabia.

• · Agro business was sluggish in the period due to El Niño, a flat-to-negative segment not highlighted in the headline results
• · Profit After Tax was subdued in Q2 due to higher depreciation from investments in long-term projects
• · H1 FY27 EBITDA margin declined 40 bps to 12.0%, while Q2 margin improved 20 bps
• · Management cited raw material volatility, geopolitical uncertainty, and cautious customer behaviour as headwinds
• · New geographies added in Textile Specialty Chemicals: Peru and Indonesia
• · Strategic initiatives include monetising non-core assets and rationalising lower-margin businesses